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The circumsporozoite protein (CSP) is the major surface protein of 
 
Plasmodium
 
 sporozoites, 
the infective stage of malaria. Although CSP has been extensively studied as a malaria 
vaccine candidate, little is known about its structure. Here, we show that CSP is proteolytically 
cleaved by a papain family cysteine protease of parasite origin. Our data suggest that the 
highly conserved region I, found just before the repeat region, contains the cleavage site. 
Cleavage occurs on the sporozoite surface when parasites contact target cells. Inhibitors of 
CSP processing inhibit cell invasion in vitro, and treatment of mice with E-64, a highly 
specific cysteine protease inhibitor, completely inhibits sporozoite infectivity in vivo.
 
Malaria infection is initiated when an infected
Anopheline mosquito injects sporozoites dur-
ing a blood meal. After injection, sporozoites
enter the bloodstream and go to the liver,
where they invade hepatocytes and develop
into exoerythrocytic forms. The circumsporo-
zoite protein (CSP) is the major surface protein
of the sporozoite and forms a dense coat on
the parasite’s surface. Studies have shown that
CSP mediates sporozoite adhesion to target
cells (for review see reference 1) and that it is
required for sporozoite development in the
mosquito (2). In addition, CSP has been ex-
tensively studied as a vaccine candidate and,
thus far, is the only 
 
Plasmodium
 
 protein shown
to confer protection to immunized individuals
(for review see reference 1).
Comparison of the deduced amino acid se-
quences of CS proteins from all species of 
 
Plasmo-
dium
 
 shows that they have a similar overall struc-
ture (see Fig. 1 A and reference 1). They all
contain a central repeat region whose amino acid
sequence is species specific and two conserved
regions: a five amino acid sequence called region
I, immediately before the repeats, and a known
cell-adhesive sequence with similarity to the
type I thrombospondin repeat (TSR; reference
3). CSP has a canonical glycosylphosphatidyl
inositol  (GPI) anchor addition sequence in its
COOH terminus; however, the presence of a
GPI anchor has not been demonstrated.
It was noted 20 yr ago that CSP immuno-
precipitated from sporozoite lysates consists of
one to two high MW bands (that differ by 
 
 
 
1
kD) and a low MW band that is 8–10 kD
smaller (4, 5). Biosynthetic studies showed that
the initial label is incorporated into the top
bands and the lower MW band appears later as
a processed product (4, 5). The precise nature
of this processing, as well as its functional sig-
nificance, have remained unknown. In this re-
port, we have determined the structural basis
for this conserved feature of CSPs and have
explored its role during sporozoite invasion of
hepatocytes.
 
RESULTS AND DISCUSSION
The NH
 
2
 
-terminal portion of CSP is 
proteolytically cleaved by a cysteine protease
 
To study the structure of the high and low
MW CSP forms, we made polyclonal antisera
to peptides representing the entire NH
 
2
 
-terminal
and COOH-terminal thirds of CSP from 
 
Plas-
modium berghei
 
, a rodent malaria parasite. These
antisera recognized the appropriate full-
length peptides (Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20040989/
DC1)  and did not recognize peptides repre-
senting the central repeat domain (Fig. S1 B). In
addition, the NH
 
2
 
-terminal antiserum did not
recognize the COOH-terminal peptide and
the COOH-terminal antiserum did not recog-
nize the NH
 
2
 
-terminal peptide (unpublished
data). Western blot analysis of a 
 
P. berghei
 
sporozoite lysate showed that the NH
 
2
 
-termi-
nal antiserum recognized only the high MW
CSP form, indicating that all or part of the
NH
 
2
 
 terminus is proteolytically cleaved to
generate the low MW CSP form (Fig. 1 B). In
contrast, mAb 3D11 (which recognizes the re-
peat region) and the COOH-terminal anti-
serum recognized both CSP forms.
 
The online version of this article contains supplemental material.
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To determine what class of protease was responsible for
cleavage, we performed pulse-chase metabolic labeling ex-
periments in the presence of different protease inhibitors. We
labeled sporozoites with [
 
35
 
S]Cys/Met and chased with cold
medium containing the indicated inhibitor (Fig. 1 C). In the
absence of protease inhibitors, 
 
 
 
80% of labeled CSP was
cleaved after 2 h. In the presence of the metalloprotease in-
hibitor 1,10 phenanthroline or the aspartyl-protease inhibitor
pepstatin, there was no effect on CSP processing. In addition,
EDTA had no effect on CSP processing, indicating that diva-
lent cations are not required. 
 
L
 
-transepoxysuccinyl-leucyl-
amide-[4-guanido]-butane (E-64), a highly specific cysteine
protease inhibitor, and PMSF, a serine protease inhibitor, in-
hibited CSP processing. Leupeptin and TLCK, inhibitors of
both cysteine and serine proteases, also inhibited processing.
Although PMSF has been reported to have inhibitory activity
against some papain family cysteine proteases (6), it is a proto-
typical serine protease inhibitor. To further examine the role
of serine proteases, we assayed two other serine protease in-
hibitors, aprotinin and 3,4 dichloroisocoumarin (3,4 DCI).
Aprotinin inhibits most classes of serine proteases and would
be predicted to inhibit the serine proteases of 
 
Plasmodium
 
,
which are subtilisin-like (7). 3,4 DCI is a serine protease in-
hibitor that has some activity against cysteine proteases but
does not react with papain-like cysteine proteases (8). Nei-
ther compound had an effect on CSP processing.
We also performed pulse-chase metabolic labeling exper-
iments with the human malaria parasite, 
 
Plasmodium falci-
parum
 
, and found that E-64 inhibited CSP processing in this
species (Fig. 1 D). These data suggest that CSP cleavage oc-
curs by a similar mechanism in both rodent and human 
 
Plas-
modium
 
 species.
To ensure that the protease inhibitors were not toxic to
sporozoites, we incubated sporozoites with the different in-
hibitors and added propidium iodide, a dye that is excluded
by viable cells but penetrates membranes of dying cells. The
percentage of sporozoites that took up the dye in the pres-
ence of any of the protease inhibitors was no different from
controls (unpublished data). In addition, we tested whether
sporozoites incubated with protease inhibitors were less met-
abolically active. Analysis of CSP synthesis after sporozoites
had been incubated with individual inhibitors for 2 h
showed that it was not affected by E-64, leupeptin, or PMSF
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20040989/DC1).
Our data suggest that the processing enzyme is a cysteine
protease. The cysteine proteases found in parasites are mem-
bers of two clans, CA (papain-like) and CD (legumin-like)
(for review see reference 9), which can be distinguished by
their sensitivity to E-64. The protease that cleaves CSP is in-
hibited by E-64 and, therefore, is a Clan CA, papain family
cysteine protease. However, we found that PMSF, a serine
protease inhibitor, also inhibited processing. As stated before,
PMSF has been reported to have activity against papain fam-
ily cysteine proteases and this could explain its inhibitory ac-
tivity in our processing assay. Nonetheless, it is also possible
that CSP cleavage is a complex multistep process involving
distinct proteases.
 
Region I likely contains the cleavage site
 
To determine where CSP is cleaved, we mapped the epi-
topes recognized by the NH
 
2
 
-terminal antiserum using
overlapping peptides. As shown in Fig. 2 A, the NH
 
2
 
-termi-
nal antiserum recognized peptides interspersed throughout
the NH
 
2
 
-terminal third of the protein, suggesting that the
processed form lacks this entire region. These data raised the
intriguing possibility that region I, found at the end of
the NH
 
2
 
 terminus, contained the cleavage site. To test this,
we used a recombinant 
 
P. berghei
 
 parasite in which the last
21 amino acids of the NH
 
2
 
 terminus and the entire repeat
region had been replaced by the orthologous region from 
 
P.
falciparum
 
 CSP [Pf/Pb sporozoites; Fig. 2 B and reference
10). A Western blot of Pf/Pb sporozoites shows that both
Figure 1. CSP is proteolytically cleaved by a cysteine protease. (A) CS 
proteins from all species of Plasmodium have several conserved features: 
a central repeat region (gray box) and two conserved regions (black boxes, 
region I and the cell-adhesive TSR). The first 20 residues of CSP have the 
features of a eukaryotic signal sequence (reference 28) and the COOH-
terminal sequence contains a canonical GPI-anchor addition site. Bars 
show the location of peptides used for the generation of antisera. (B) 
Western blot of a P. berghei sporozoite lysate probed with polyclonal anti-
sera generated against the NH2- and COOH-terminal peptides shown in A; 
mAb 3D11 was used as a control. The membrane was cut where indicated 
so that it could be probed with the three different antisera, and the mem-
brane strips were developed together. (C) P. berghei sporozoites were met-
abolically labeled and kept on ice (lane 1) or chased for 2 h in the absence 
(lane 2) or presence of the indicated protease inhibitors (lanes 3–11). CSP 
was immunoprecipitated from lysates of sporozoites and analyzed by 
SDS-PAGE and autoradiography. The following inhibitors were used: 
10  M E-64, 1 mM PMSF, 0.3  M aprotinin, 100  M 3,4 DCI, 75  M leu-
peptin, 100  M TLCK, 1  M pepstatin, 1 mM 1,10 phenanthroline, and 
5 mM EDTA. All samples are from the same experiment but were run on 
two gels and grouped as indicated. (D) P. falciparum sporozoites were 
metabolically labeled and kept on ice (lane 1) or chased with cold medium 
for 90 min in the absence (lane 2) or presence of E-64 (lane 3). Samples 
were processed as outlined before. 
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CSP forms are present, suggesting it is processed (Fig. 2 C).
We performed pulse-chase metabolic labeling experiments
with Pf/Pb sporozoites and found that after a 4-h chase, 50–
80% of the high MW CSP is processed to the low MW form
(unpublished data). When we tested whether E-64 could in-
hibit processing of the hybrid CSP, we found that it did (Fig.
2 D), indicating that the same protease cleaves both the na-
tive and hybrid CS proteins.
These data suggest that the cleavage site is found within
region I because this sequence remains unchanged in the hy-
brid protein. Although it is possible that the cleavage site is
outside of the swapped region, this is unlikely because the
NH
 
2
 
-terminal antiserum, which recognized peptides through-
out the NH
 
2
 
-terminal third of CSP, did not recognize the low
MW CSP form. Previous studies have shown that the differ-
ence in size, by SDS-PAGE, between the high and low MW
forms is 
 
 
 
8–10 kD (4, 5, 11–13). The NH
 
2
 
-terminal portion
of CSP, beginning after the signal sequence and ending just
before the repeat region, is predicted to be this size.
 
CSP cleavage occurs extracellularly by a sporozoite protease
 
We investigated the cellular location of CSP processing. Im-
munofluorescence experiments with live sporozoites showed
that they were recognized by the NH
 
2
 
-terminal antiserum,
demonstrating that full-length CSP was on the surface (Fig.
3 A). To confirm this, we biotinylated sporozoites expressing
GFP with a reagent that does not enter cells. As shown in
Fig. 3 B, the high MW CSP form is biotinylated, indicating
that it is on the surface. As a control, we immunoprecipi-
tated GFP, an intracellular protein, and found that it was not
labeled (Fig. 3 C). These findings are in agreement with a
previous paper that showed that high MW CSP was on the
surface of 
 
Plasmodium vivax
 
 sporozoites (12) and suggest that
processing occurs on the sporozoite surface.
In contrast with our findings, other investigators found
that the majority of CSP on the surface was the low MW
form, and concluded that processing occurred intracellularly
(4, 5). In these studies, CSP was immunoprecipitated from
sporozoites that were metabolically labeled and trypsinized.
When compared with controls, trypsin-treated sporozoites
were primarily missing the low MW CS band, indicating that
the high MW CSP form was intracellular. However, in these
experiments, trypsin was added immediately after labeling,
which may not have allowed sufficient time for export of all
the labeled CSP to the sporozoite surface. To investigate
whether this was the case, we repeated this experiment and
incorporated a chase into the experimental design. Sporo-
zoites were metabolically labeled and kept on ice or chased in
the presence of cyclohexamide to prevent further protein
Figure 2. The conserved region I likely contains the proteolytic 
cleavage site. (A) The epitopes recognized by the NH2-terminal antiserum 
were determined by ELISA by testing its reactivity to overlapping peptides 
encompassing the NH2-terminal third of CSP. Pep 1, GYGQNKSIQAQRNLNE; 
Pep 2, RNLNELCYNEGNDNKL; Pep 3, NDNKLYHVLNSKNGKI; Pep 4, 
KNGKIYIRNTVNRLLA; Pep 5, NRLLADAPEGKKNEKK; Pep 6, KNEKKNKIERNNKLK; 
and N-term, full-length NH2-terminal peptide. (B–D) Proteolytic cleavage 
of hybrid CSP. (B) Structure of CSP from Pf/Pb sporozoites. The portion of 
P. berghei CSP that has been replaced with the orthologous sequence of 
P. falciparum CSP is shown in orange and includes region I, which is shown 
in black. (C) Western blot of Pf/Pb sporozoites probed with mAb 2A10, 
directed against the P. falciparum CSP repeat region. (D) Pf/Pb sporozoites 
were metabolically labeled and kept on ice (lane 1) or chased with cold 
medium for 4 h, in the absence or presence of E-64. Samples were pro-
cessed as outlined in Fig. 1.
Figure 3. CSP is processed extracellularly by a parasite protease. 
(A) Staining of live sporozoites with the NH2-terminal antiserum. Phase 
contrast and fluorescence views are shown. Bar, 10  m. (B and C) P. berghei 
sporozoites expressing GFP were biotinylated, lysed, and CSP (B) and GFP 
(C) were immunoprecipitated. A Western blot of the immunoprecipitated 
material was probed with streptavidin (B and C, lane 1), mAb 3D11 (B, lane 
2), or polyclonal antisera to GFP (C, lane 2). The membrane was cut where 
indicated so that it could be probed with individual antisera and, the 
membrane strips were developed together. (D) Metabolically labeled 
P. berghei sporozoites were kept on ice (time   0) or chased for 1 h, and 
incubated in medium containing pronase ( ) or pronase plus pronase 
inhibitor cocktail ( ). CSP was immunoprecipitated from sporozoite lysates 
and analyzed by SDS-PAGE and autoradiography. (E) P. berghei sporozoites 
were dissected and purified in the absence ( ) or presence ( ) of E-64, 
washed, metabolically labeled, and either kept on ice (time   0) or chased 
for 2 h. Sporozoites were lysed, and CSP was immunoprecipitated and 
analyzed by SDS-PAGE and autoradiography. 
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synthesis. Next, they were treated with pronase or pronase
plus an inhibitor cocktail. As shown in Fig. 3 D, if the para-
sites were kept on ice after labeling, the high MW CSP was
not digested by pronase. However, if sporozoites were chased
before pronase treatment, both CSP forms were digested, in-
dicating that both forms were found on the sporozoite’s sur-
face, making this the likely location of processing.
Sporozoites isolated from salivary glands of infected
mosquitoes are invariably contaminated with mosquito de-
bris, raising the possibility that the protease that cleaves CSP
is of mosquito origin. To address this question, we dissected
and purified sporozoites in the presence of E-64, and then
metabolically labeled them in medium without E-64. Cys-
teine proteases of mosquito origin would be extracellular
and, therefore, irreversibly inhibited by the E-64 present
during sporozoite isolation. However, we found that CSP
was processed with the same kinetics regardless of whether
sporozoites were purified in the presence or absence of
E-64. These data suggest that the protease was synthesized
(or secreted) after the removal of E-64 and, therefore, was
of sporozoite origin (Fig. 3 E).
 
CSP cleavage is required for cell invasion
 
Proteolytic cleavage of cell surface and secreted proteins oc-
curs during invasion of erythrocytes by the merozoite stage
of 
 
Plasmodium
 
 (for review see reference 14). To determine
whether CSP cleavage was required for sporozoite entry into
cells, a variety of protease inhibitors were tested for their
ability to inhibit sporozoite invasion of a hepatocyte cell line.
As shown in Fig. 4 A, E-64 inhibited invasion by 90% and
PMSF and leupeptin also had inhibitory activity. Pepstatin
had no effect on invasion and the serine protease inhibitors
aprotinin and DCI, which do not have activity against the
papain family cysteine proteases, also did not have inhibitory
activity on invasion. Importantly, pretreatment of target cells
with E-64 had no inhibitory effect on sporozoite invasion.
The ability of E-64 to inhibit invasion was not restricted to
 
P. berghei
 
 sporozoites, as invasion by both 
 
P. yoelii
 
 and 
 
P. fal-
ciparum
 
 sporozoites was also inhibited by E-64. Notably, the
number of extracellular sporozoites was always enhanced in
the presence of E-64, suggesting that there was an accumula-
tion of attached sporozoites that were prevented from enter-
ing (Fig. 4 B). Because attachment to cells is a distinct stage
Figure 4. E-64 inhibits sporozoite infectivity in vitro and in vivo but not sporozoite migration through cells. (A) The effect of protease inhibitors 
on cell invasion by Plasmodium sporozoites. P. berghei (gray bars), P. yoelii (white bar), or P. falciparum (black bar) sporozoites were preincubated with the 
indicated protease inhibitors before being added to cells. A control (diagonally striped bar) was performed in which the target cells were preincubated with 
E-64, the medium was removed, and untreated P. berghei sporozoites were added. The following inhibitors were used: 10  M E-64, 1 mM PMSF, 75  M 
leupeptin, 0.3  M aprotinin, 100  M 3,4 DCI, and 1  M pepstatin. Each point was performed in triplicate, 50 fields/well were counted, and the means   
SD are shown. Inhibition of invasion was calculated based on the invasion rate for sporozoites pretreated with buffer alone, which was 54% for 
P. berghei, 26% for P. yoelii, and 52% for P. falciparum. (B) Shown are the numbers of extracellular sporozoites when sporozoites are preincubated in the 
absence (gray bars) or presence (white bars) of E-64. Data are from the invasion assay shown. (C) Shown are the numbers of dextran-positive cells when 
sporozoites were preincubated   E-64 and added to cells in the presence of rhodamine–dextran. Each point was performed in triplicate, 50 fields/coverslip 
were counted, and shown are the means   SD. (D) E-64 inhibits sporozoite infectivity in vivo. Mice were injected with E-64 or buffer alone before inocu-
lation of P. yoelii sporozoites. 40 h later, the mice were killed, total liver RNA was extracted, and malaria infection was measured by quantitative PCR. In-
fection is expressed as the number of copies of P. yoelii 18S rRNA. Results from two experiments are shown. There were six mice per group per experiment. 
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of sporozoite invasion (15), these results suggest that E-64
specifically blocks invasion and that attachment to cells does
not require proteolytic cleavage of CSP.
These data suggest that CSP is cleaved during cell inva-
sion. Therefore, we predicted that intracellular sporozoites
would lose their reactivity to the NH
 
2
 
-terminal antiserum,
which recognizes only full-length CSP. However, we found
that the majority of sporozoites associated with cells lost
their reactivity to the NH
 
2
 
-terminal antiserum regardless of
whether they were intracellular or extracellular (unpublished
data). In the absence of cells, 80–90% of sporozoites stained
with this antiserum (unpublished data), suggesting that cell
contact was the trigger for CSP cleavage. To test this, sporo-
zoites were preincubated with cytochalasin D (CD), an in-
hibitor of sporozoite invasion but not attachment to cells
(15), in the presence or absence of E-64 and added to cells.
As shown in Table I, sporozoites incubated with CD plus
E-64 stained with the NH
 
2
 
-terminal antiserum, whereas those
incubated with CD alone did not. mAb 3D11, directed
against the repeat region of CSP, bound to both E-64–
treated and untreated sporozoites. Controls in which sporo-
zoites were incubated without cells showed that neither ele-
vated temperature nor serum alone had a significant effect on
CSP cleavage (Table I).
In this assay, sporozoites were incubated with cells for
only 2 min before being fixed and stained. The rapid loss of
reactivity to the NH
 
2
 
-terminal antiserum indicates that there
is a dramatic increase in the kinetics of CSP cleavage when
parasites are added to cells. In the absence of cells, the half
life of newly synthesized CSP is 
 
 
 
1 h (Fig. 1 and references
4, 5). These data indicate that the secretion of the protease
that cleaves CSP is regulated. It is likely that the low level
cleavage observed in the absence of cells is due to leaky se-
cretion from apical organelles, whereas exocytosis of larger
amounts of protease is mediated by specific signals that are
transduced upon contact with target cells.
 
CSP cleavage is not required for migration through cells
 
It has been shown that sporozoites interact with cells in two
distinct ways: they either rupture the plasma membrane and
migrate through a cell or they enter with a vacuole and pro-
ductively invade the cell (16). To study whether CSP pro-
cessing was preferentially associated with one of these processes,
we tested whether E-64 inhibited sporozoite migration through
cells. Migration can be quantified by including a high MW
fluorescent tracer in the medium because it will enter cells
that are wounded by sporozoites as they pass through. As
shown in Fig. 4 C, E-64 had no effect on sporozoite migra-
tion through cells.
These data indicate that CSP cleavage is associated with
productive invasion of cells and suggests that sporozoites dif-
ferentially recognize cells that they will invade; a finding that
makes sense given that, in vivo, they travel through several
cell barriers to reach their target, the hepatocyte. One ques-
tion raised by these findings is how do sporozoites recognize
hepatocytes? Previous work has shown that CSP binds to
heparan sulfate proteoglycans (HSPGs) found on hepato-
cytes, making these molecules likely candidates for target cell
recognition (for review see reference 1). We are currently
investigating whether binding of CSP to HSPGs triggers
cleavage and initiates the cascade of events leading to pro-
ductive invasion of cells.
 
Inhibition of cysteine proteases prevents malaria infection
 
Lastly, we tested E-64 as an inhibitor of malaria infection in
vivo using a rodent model of the disease. Using a quantita-
tive PCR assay, we compared the amounts of parasite rRNA
in the livers of mice pretreated with E-64 or buffer and in-
fected with 
 
Plasmodium
 
 sporozoites. We found that mice in-
jected with E-64 were completely protected from malaria
infection (Fig. 4 D). Although inhibitors of cysteine and
serine proteases have not yet been used for the treatment of
human disease, animal studies have shown the feasibility of
using these inhibitors as drugs in the treatment of parasitic
infections (for review see references 17, 18). Our finding
that we can completely prevent malaria infection by target-
ing the cysteine proteases of the sporozoite stage could lead
to the development of new prophylactic agents for malaria.
In conclusion, we have shown that the high MW CSP
form is proteolytically cleaved by a papain family cysteine
protease of parasite origin. Several lines of evidence support
a role for CSP cleavage during cell invasion. First, under
conditions in which CSP cleavage is inhibited, cell invasion
is similarly inhibited. Second, rapid and complete CSP
cleavage occurs when sporozoites contact target cells, indi-
cating that cleavage is temporally associated with invasion.
 
Table I.
 
Contact with hepatocytes triggers cleavage of CSP
 
Experiment Cells Condition
 
a
 
Method for 
sporozoite
visualization
Number of 
sporozoites
visualized
 
b
 
1
 
Hepa 1-6 CD 3D11 244 
 
 
 
 3
Hepa 1-6 CD + E-64 3D11 230 
 
 
 
 4
Hepa 1-6 CD
 
 
 
-N 41 
 
 
 
 1
Hepa 1-6 CD + E-64
 
 
 
-N 237 
 
 
 
 5
no cells control
 
 
 
-N 80% 
 
 
 
 0.4
no cells CD
 
 
 
-N 85% 
 
 
 
 1.1
no cells E-64
 
 
 
-N 90% 
 
 
 
 4.1
no cells CD + E-64
 
 
 
-N 84% 
 
 
 
 0.5
no cells CD + 10% serum
 
 
 
-N 80% 
 
  3.7
2 Hepa 1-6 CD GFP 452   8
Hepa 1-6 CD  -N 98   2
Hepa 1-6 CD + E-64 GFP 444   6
Hepa 1-6 CD + E-64  -N 436   8
aP. berghei sporozoites (wild type in experiment 1; GFP in experiment 2) were prein-
cubated   E-64, and before addition to coverslips, CD was added to the indicated 
samples. Sporozoites were spun onto coverslips, with or without cells as indicated, 
brought to 37 C for 2 min, fixed, and stained with the indicated antisera.
bEach point was plated in duplicate, 50 fields/coverslip were counted, and the 
means   SD are shown. When sporozoites were plated without cells, 100–200 
sporozoites/coverslip were counted, and the percentage staining with the NH2-
terminal antiserum is shown.PROTEOLYTIC PROCESSING OF THE CS PROTEIN | Coppi et al. 32
And lastly, the conservation of this process across the genus
indicates that it is of importance to the parasite.
These data are part of a growing body of work demon-
strating that proteolytic processing of secreted and surface
proteins is required for cell invasion by Plasmodium and other
Apicomplexan parasites such as Toxoplasma (14, 19, 20). One
of the most well-studied examples is MSP-1, the major sur-
face protein of Plasmodium merozoites, the infective form of
the erythrocytic stage (for review see reference 14). Interest-
ingly, both CSP and MSP-1 have known cell-adhesive do-
mains in their COOH termini, raising the possibility that
cleavage controls the exposure of these domains. In CSP, the
COOH terminus contains the TSR, a known cell-adhesive
sequence that has been shown to bind with high affinity to
HSPGs (for review see reference 1). Previous studies have
shown that the NH2-terminal portion of CSP also binds to
HSPGs (21). Our data suggest a model for CSP cleavage that
explains why this protein has two heparin-binding domains.
Our hypothesis is that an initial interaction between cell sur-
face HSPGs and the NH2-terminal portion of CSP cross-
links the protein and provides the signal for cleavage. In
turn, cleavage exposes the cell-adhesive TSR, which binds
with high affinity to HSPGs, initiating a cascade of events
that ultimately lead to cell entry.
MATERIALS AND METHODS
Antibodies and peptides. mAb 3D11 is directed against the repeat re-
gion of P. berghei CSP (22); mAb NYS1 is directed against the repeat region
of P. yoelii CSP (23); and mAb 2A10 is directed against the repeat region of
P. falciparum CSP (11). For immunoprecipitations, mAbs 3D11 and 2A10
were conjugated to sepharose as outlined previously (24). Antisera to the
NH2- and COOH-terminal thirds of P. berghei CSP were generated in
rabbits using peptides that were provided by G. Corradin and M. Roggero
(Institute of Biochemistry, Lausanne, Switzerland). The sequences of the
NH2- and COOH-terminal peptides were GYGQNKSIQAQRNLN-
ELCYNEGNDNKLYHVLNSKNGKIYIRNTVNRLLADAPEGKKNE-
KKNKIERNNKLK and NDDSYIPSAEKILEFVKQIRDSITEEWSQC-
NVTCGSGIRVRKRKGSNKKAEDLTLEDIDTEICKMDKCS, respectively.
Overlapping peptides and repeat peptides were synthesized and purified by
Midwest Bio-Tech.
Sporozoites. P. yoelii, P. berghei, P. berghei–expressing GFP (25), and re-
combinant P. berghei sporozoites expressing a hybrid P. berghei–P. falciparum
CSP (Pf/Pb sporozoites; reference 10) were grown in Anopheles stephensi
mosquitoes.  P. falciparum–infected mosquitoes were obtained from D.
Carucci (Naval Medical Research Center Malaria Program, Silver Spring,
MD). Where indicated, sporozoites were purified by passage through two
3- m polycarbonate membranes (Whatman).
ELISAs. Peptides were coated onto wells of Immunlon 2HB microtiter plates
(ThermoLabsystems) and blocked, and antisera were added at the indicated di-
lutions. Binding was revealed with anti–mouse or anti–rabbit Ig-conjugated to
alkaline phosphatase followed by the fluorescent substrate, 4-methylumbel-
liferyl phosphate and fluorescence was read in a Fluoroskan II plate reader.
Metabolic labeling.  P. berghei or where indicated, P. falciparum or Pf/Pb
sporozoites, were metabolically labeled in DMEM without Cys/Met, 1%
BSA, and 400  Ci/ml L-[35S]Cys/Met for 1 h at 28 C and chased in
DMEM with Cys/Met and 1% BSA at 28 C in the presence or absence of
the indicated protease inhibitor. For the pronase experiment, sporozoites
were metabolically labeled in medium without BSA for 45 min at 28 C,
washed, and resuspended in DMEM with Cys/Met and 100  g/ml cyclo-
heximide for 10 min and kept on ice or chased at 28 C for 1 h. Sporozoites
were resuspended in 100  g/ml pronase,   pronase inhibitor cocktail (500
 g/ml antipain, 30  g/ml aprotinin, 600  g/ml chymostatin, 5 mg/ml
EDTA, 5  g/ml leupeptin, 10 mg/ml AEBSF, 7  g/ml pepstatin, and 2
mM PMSF; reference 26) for 1 h at 4 C, washed, and lysed in lysis buffer
with pronase inhibitor cocktail and 1% BSA; CSP was immunoprecipitated.
Immunoprecipitation and SDS-PAGE analysis. Metabolically la-
beled sporozoites were lysed in lysis buffer (1% Triton X-100, 150 mM NaCl,
50 mM Tris-HCl, pH 8.0) with protease inhibitors for 1 h at 4 C, and lysates
were incubated with mAb 3D11 agarose overnight at 4 C and washed with
lysis buffer and lysis buffer with 500 mM NaCl and preelution buffer (0.5%
Triton X-100, 10 mM Tris-HCl, pH 6.8). CSP was eluted with 1% SDS in
0.1 M glycine, pH 1.8, neutralized with Tris-HCl, pH 8.8, and run on a 7.5%
SDS–polyacrylamide gel under nonreducing conditions. For experiments
with P. falciparum or Pf/Pb sporozoites, a 10% SDS–polyacrylamide gel was
used. Gels were fixed, enhanced with Amplify (Amersham Biosciences),
dried, and exposed to film.
Immunoblot of sporozoite lysates.  Sporozoite lysates were separated
by SDS-PAGE, transferred to PVDF membrane, and incubated with either
4  g/ml mAb 3D11, NH2-terminal antiserum (1:3,000), COOH-terminal
antiserum (1:3,000), or 4  g/ml mAb 2A10 followed by anti–mouse or
anti–rabbit Ig conjugated to horseradish peroxidase (HRP; 1:100,000).
Bound antibodies were visualized using the enhanced chemiluminescence
detection system (ECL).
Biotinylation of sporozoites. P. berghei transgenic for GFP was biotinyl-
ated using sulfo-succinimidyl-6 -(biotinamido) hexanoate according to the
manufacturer’s instructions (Pierce Chemical Co.). Lysates of biotinylated
sporozoites were immunoprecipitated with either mAb 3D11 or polyclonal
antibodies to GFP (1:200; Molecular Probes) followed by protein A cou-
pled to agarose beads, loaded onto a 4–12% Tris-Glycine gel, transferred to
PVDF, and incubated with either mAb 3D11 followed by anti–mouse Ig
HRP, anti-GFP Ig (1:500) followed by anti–rabbit Ig HRP, or streptavi-
din–HRP (1:100,000). Bound antibodies were visualized using ECL.
Immunofluorescence assay. Live P. berghei sporozoites were incubated
with NH2-terminal antiserum (1:500 in DMEM/BSA) at 4 C for 2 h,
washed at 4 C, and allowed to air dry on slides at 4 C. They were incu-
bated with anti–rabbit Ig-FITC, washed, and mounted.
Sporozoite invasion assay. Invasion assays were performed as described
previously (15), with some modifications. For assays with P. berghei and P.
yoelii, Hepa 1–6 cells (CRL-1830; American Type Culture Collection)
were used, and for assays with P. falciparum, HepG2 cells (HB-8065; Amer-
ican Type Culture Collection) were used. Sporozoites were preincubated
with the indicated protease inhibitor for 2 h at 28 C and plated on cells in
the continued presence of the inhibitor for 1 h at 37 C. In a control, Hepa
1–6 cells were incubated with 10  M E-64 for 2 h at 37 C, the medium
was removed, and untreated P. berghei sporozoites were added. After incu-
bation with sporozoites, cells were washed and fixed, and sporozoites were
stained with a double-staining assay that distinguishes between extracellular
and intracellular sporozoites.
Cell contact assay.  P. berghei sporozoites were incubated in DMEM  
10  M E-64 at 4 C for 2 h and added to Hepa 1–6 cells on glass coverslips.
30 min before sporozoites were added to coverslips, CD was added to all
samples (final concentration, 1  M). Sporozoites were centrifuged onto
coverslips (1,250 g) for 5 min at 4 C. Coverslips were brought to 37 C for 2
min, fixed with 4% paraformaldehyde, and stained with either mAb 3D11
followed by anti–mouse Ig FITC or the NH2-terminal antiserum followed
by anti–rabbit Ig FITC. When P. berghei sporozoites expressing GFP were
used, the cells were only stained with the NH2-terminal antiserum. As aJEM VOL. 201, January 3, 2005 33
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control, sporozoites were spun onto coverslips without cells using the afore-
mentioned protocol.
Sporozoite migration assay.  Sporozoites were preincubated  10  M
E-64 for 2 h at 28 C and added to Hepa 1–6 cells in the continued presence
of inhibitor with 1 mg/ml rhodamine-dextran. After 1 h at 37 C, the cells
were washed and fixed, and rhodamine-positive cells were counted as out-
lined previously (16).
Assay for sporozoite infectivity in vivo. Swiss/Webster mice were
given three i.p. injections of DMEM   E-64 (50 mg/kg/injection) at 16,
2.5, and 1 h before i.v. injection of 15,000 P. yoelii sporozoites. 40 h later,
livers were harvested, total RNA was isolated, and malaria infection was
quantified using reverse transcription followed by real-time PCR using
primers that recognize P. yoelii–specific sequences within the 18S rRNA as
outlined previously (27). 10-fold dilutions of a plasmid construct containing
the P. yoelii 18S rRNA gene were used to create a standard curve.
Online supplemental material. Fig. S1 shows the specificity of the
NH2- and COOH-terminal antisera as determined by ELISA. Fig. S2
shows that the protease inhibitors that inhibited CSP processing are not
toxic to sporozoites. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20040989/DC1.
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